Vivos Therapeutics, Inc. has taken a significant step by filing a definitive additional proxy statement, as noted in their recent SEC filing. This move is crucial for the company as it prepares for upcoming shareholder votes on various corporate matters. Engaging with shareholders is essential for maintaining trust and transparency, especially in the competitive landscape of the surgical and medical instruments industry.

Founded in 2015, Vivos Therapeutics operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. The company is publicly traded on the Nasdaq under the ticker symbol VVOS. Vivos Therapeutics focuses on developing innovative solutions for various medical needs, particularly in the realm of sleep apnea and related disorders.

The recent filing, dated November 2, 2026, is categorized as a definitive additional proxy statement. While the specific details of the shareholder votes were not disclosed in the filing, such documents typically outline important proposals that shareholders will be asked to approve. This could include matters such as board elections, executive compensation, or other governance-related issues.

This filing is likely to impact various stakeholders, including shareholders, company executives, and potentially even competitors within the surgical and medical instruments industry. As Vivos Therapeutics seeks to strengthen its corporate governance practices, other companies in the sector may feel compelled to enhance their own shareholder engagement efforts.

Looking ahead, Vivos Therapeutics may continue to provide updates on the outcomes of the shareholder votes and any subsequent actions resulting from the decisions made. The filing does not specify what happens next, but it sets the stage for increased shareholder involvement in the company's future direction.